Clinical Trial Update: Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy of B7-H3 CAR T cells given after upfront MAP chemotherapy in newly diagnosed high-risk pediatric osteosarcoma; cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• B7-H3-CAR T cells (B7-H3-targeted CAR T cells)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Pediatric Osteosarcoma | Phase 2 | Status: NOT_YET_RECRUITING